TAK-505

PreclinicalSmall molecule

Takeda

TAK-505 is one of 63 small molecule programs targeting Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorsNot yet recruiting

Malignant Solid TumorsRecruiting

Solid TumorsPreclinical

Not yet recruiting

Malignant Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

137 competitors in Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

6 2

Lynparza

AstraZeneca

Phase 3

4 3

Lenvima

Eisai

Phase 3

3 4

Taxol

Teva

Phase 2

15 5

Gemzar

Johnson & Johnson

Phase 2

12 6

Opdivo

Bristol-Myers Squibb

Phase 2

10 7

Beyfortus

BeiGene

Phase 2

5 8

Camptosar

Pfizer

Phase 2

3 9

Fludara

Sanofi

Phase 2

3 10

Taxotere

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalRecruiting

Malignant Solid Tumors

NCT07436728

Clinical

Trials by Indication[1]

Malignant Solid Tumors1 trial

A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Recruiting· Takeda logo

Takeda·Preclinical·NCT07436728·151 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAK-505. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-505 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-505. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Takeda

TAK-505

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News